Superior cervical ganglia 10 (SCG10), as a microtubule (MT) destabilizer, maintains MT homeostasis and has a critical role in neuronal development, but its function in tumorigenesis has not been characterized. In the present study, we demonstrated that p21-activated kinase 4 (PAK4)-mediated SCG10 phosphorylation regulates MT homeostasis in metastatic gastric cancer. Our results indicate that SCG10 is a physiological substrate of PAK4, which is phosphorylated on serine 50 (Ser50) in a PAK4-dependent manner. Phosphorylated SCG10 regulated MT dynamics to promote gastric cancer cell migration and invasion in vitro and metastasis in a xenograft mouse models. Inhibiting PAK4, either by LCH-7749944 or RNA interference, resulted in the inhibition of Ser50 phosphorylation and a blockade to cell invasion, suggesting that PAK4-SCG10 signaling occurs in gastric cancer cell invasion. Moreover, we demonstrated a strong positive correlation between PAK4 and phospho-Ser50 SCG10 expression in gastric cancer samples. We also showed that high expression of SCG10 phospho-Ser50 is highly correlated to an aggressive phenotype of clinical gastric cancer. These findings revealed a novel function of SCG10 in promoting invasive potential of gastric cancer cells, suggesting that blocking PAK4-mediated SCG10 phosphorylation might be a potential therapeutic strategy for metastasis of gastric cancer.
INTRODUCTION
Gastric cancer is a common malignant gastrointestinal tumor and is the second leading cause of cancer-related death worldwide. Tumor invasion and metastasis are critical steps in determining aggressive phenotypes of human cancers and are fundamentally related to cancer deaths. 1 Identifying the proteins that govern metastasis and the discovery of novel prognostic markers and therapeutic targets are, therefore, important steps for improving cancer patient survival.
The p21-activated kinases (PAKs) are a family of serine/threonine protein kinases that were first identified as major effectors of the small Rho GTPases-Rac1 and Cdc42. PAKs have been shown to have a pivotal role in cytoskeletal reorganization, survival, gene regulation, motility and tumorigenesis. 2 Six mammalian p21-activated kinases (PAKs) are have been classified into two groups as follows: Group I (PAK1-3), Group II (PAK4-6).
2 PAK4 was first identified as an effector of Cdc42 regulation of cytoskeleton reorganization. 3 It has since been shown to participate in a wide range of biological functions, protecting cells from apoptosis, 4 inhibiting cell adhesion, 5, 6 promoting cell migration, [7] [8] [9] [10] tumorigenesis 11 and anchorage-independent growth. 12 Overexpression of PAK4 has been detected in breast, prostate, gall bladder, stomach and ovarian cancer cell lines, 8, [12] [13] [14] as well as in several primary tumors. 15 PAK4 overexpression has been shown to cause tumor formation in athymic mice, 15 whereas depletion of PAK4 inhibits tumorigenesis. 16 There is mounting evidence to show that PAK4 is intimately related to the progression and metastasis of cancer, indicating that it may become a promising diagnostic and therapeutic target for use in oncology. 14 To further investigate this possibility, we studied the effects of novel binding partners and substrates of PAK4.
SCG10 (superior cervical ganglia 10, stathmin 2) is a member of the stathmin family, which also includes stathmin 1 (synonymous with oncoprotein 18/Op18), stathmin-like 3 (SCG10-like protein; SCLIP) and stathmin-like 4 (RB3 with two splice variants, RB3 0 and RB3 00 ). 17, 18 SCG10, acts as a microtubule (MT) destabilizer, has a critical role in neuronal development 19, 20 and cell motility. 21, 22 The ability of SCG10 to negatively regulate MT stability is inhibited by phosphorylation of up to four residues (serine 50, 62, 73 and 97) or by mutations that simulate phosphorylation. 17, 19 Interestingly, a mutant of SCG10 phosphorylated only on Ser50 has been shown to retain the ability to depolymerize MTs, 23 indicating that the biological functions of phosphorylation at Ser50 are different from those of serine 62, 73 and 97. Stathmin 1 (STMN1/Op18) is ubiquitously expressed, but SCG10 (STMN2) is generally considered to be a neuron-specific protein. 24, 25 The function of SCG10 in gastric cancer has not yet been investigated. In this study, we showed that SCG10 is a physiological substrate of p21-activated kinase 4 (PAK4). Phosphorylation of SCG10 on serine 50 by PAK4 promoted gastric cancer cell invasion in vitro and metastasis in vivo. There was a strong positive correlation between PAK4 and phospho-Ser50 SCG10 expression in gastric cancer samples, and high expression of SCG10 phospho-Ser50 was positively correlated with an aggressive phenotype of clinical gastric cancer.
RESULTS

SCG10 is a physiologic substrate of PAK4 kinase
To identify novel PAK4-binding partners, we performed yeast two-hybrid screening using a human fetal brain complementary DNA library with the N-terminal of PAK4 (PAK4-binding domain) as bait and identified SCG10 as a presumed binding protein (Supplementary Figure 1a) . In order to verify the potential interaction obtained with the yeast two-hybrid screening, we performed in vitro glutathione S-transferase (GST)-binding assay and showed that invitro-translated PAK4 interacts with GST-SCG10 but not with GST alone (Figure 1a ). Exogenous immunoprecipitation assays were then undertaken to test the intracellular interaction between PAK4 and SCG10. GST-tagged PAK4 and green fluorescent protein (GFP)-tagged SCG10, or GFP-tagged PAK4 and GST-tagged SCG10, were co-expressed in HEK-293 cells and immobilized with glutathineconjugated agarose to pull down GST-tagged PAK4 or SCG10 (Supplementary Figures 1b and c) . Figure 1 . SCG10 is a PAK4 interaction substrate. (a) PAK4 interacts with SCG10 in vitro. GST pull-down assay was performed by incubating in-vitro-translated his-tagged PAK4 with purified GST-SCG10 immobilized on glutathione-Sepharose beads. GST-SCG10 but not GST was shown to pull down PAK4. Asterisks indicate GST and GST-SCG10 bands, and coomassie staining indicates the loading amounts. (b) The interaction between endogenous PAK4 and SCG10 in SGC-7901 cells and gastric cancer tissues, analyzed by immunoprecipitation using a PAK4 antibody. (c) PAK4 phosphorylated SCG10 at Ser50 in vitro. GST, GSTSCG10 full length, GSTSCG10 S50A, S62A, S73A and S97A were used as PAK4 substrates in the PAK4 kinase assay. Histone H3 was used as a positive control. (d) (Left) BGC-823 cells stably expressing GFP vector, GFP-SCG10S50A and GFP-tagged wild-type SCG10 (GFP-SCG10WT) were subjected to SDS-polyacrylamide gel electrophoresis and western blotting analysis. Cell extracts were probed with anti-SCG10-phospho-Ser50 antibody and anti-GFP antibody. (Middle) The specificity of phospho-SCG10 ser50 antibody toward SGC-7901 cells or gastric cancer tissue extract tested by immunoblotting. (Right) Immunohistochemical staining of human gastric cancer tissues showing expression of phospho-SCG10 ser50 protein is in cancer cells. The staining was blocked by preincubation of the phosphor-SCG10 ser50 antibody with the peptide used for immunization. (e) SGC-7901 and BGC-823 cells stably overexpressing GFP-SCG10 were transiently transfected with Flag vector, Flag-PAK4 WT, Flag-PAK4 NE or Flag-PAK4 KM. Western blotting was undertaken using an antibody that specifically recognizes phosphorylated Ser50. Quantitative data (P-SCG10/total-SCG10 relative intensity) are shown. (f) Knockdown of PAK4 decreased SCG10 phosphorylation at Ser50 in SGC-7901 cells. SCG-7901 cells were stably tranduced with three different lentiviral shPAK4 or the non-targeting control shRNA (Ctrl shRNA). ShRNA #1 is a control for off target effects of the shRNA. Endogenous SCG10 phosphorylation at Ser50 was blotted with Ser50 phospho-specific antibody. (g) Activated Cdc42 resulted in upregulation of SCG10 phosphorylation at Ser50 via PAK4. SGC-7901 cells and PAK4 knockdown SGC-7901 cells were transfected with His-Cdc42Q61L. Cdc42Q61L overexpression was demonstrated by western blotting using a His antibody. SCG10 phosphorylation at Ser50 was blotted with Ser50 phospho-specific antibody. (h) SGC-7901 cells and PAK4 knockdown SGC-7901 cells were starved over night and exposed to HGF (100 ng/ml) for 15 min. PAK4 and SCG10 phosphorylation status were determined. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
SCG10 involved gastric cancer cell metastasis Q Guo et al Importantly, immunoprecipitation of endogenous PAK4 from SGC-7901 cells or gastric cancer tissues using a PAK4-specific antibody also pulled down SCG10 protein ( Figure 1b) .
As the PAK4 kinase acts on its targets mainly through phosphorylation, we next investigated whether PAK4 might phosphorylate SCG10. The results indicated showed that PAK4 phosphorylates GST-SCG10 (Figure 1c ; lane 3). To further identify the specific phosphorylation site(s) of SCG10 by PAK4, four candidate phosphorylation sites (serine 50, 62, 73 and 97) were individually substituted with alanine (termed S50A, S62A, S73A and S97A) and subjected to in vitro PAK4 kinase assays. As shown in Figure 1c , SCG10 mutant containing an alanine substitution on serine 50 (lane 4) but not on other serines (lanes 5-7) abolished PAK4-mediated phosphorylation, indicating that the serine 50 is the PAK4 phosphorylation site in SCG10 protein.
Phospho-SCG10 Ser50 antibody was used to further test the function of PAK4-mediated SCG10 phosphorylation, and its quality and availability were verified (Figure 1d ). We next demonstrated that constitutively activated PAK4 (PAK4 NE) and wild-type PAK4 (PAK4 WT), but not kinase-dead PAK4 (PAK4 KM), promoted the phosphorylation of SCG10 on serine 50 in SGC-7901 cells (an endogenous SCG10 high-expression gastric cancer cell line, see Supplementary Figure 2 ) and GPF-SCG10/BGC-823 cells (an exogenous SCG10 stable expression gastric cancer cell line, see Figure 1e ).
To demonstrate the importance of PAK4 in SCG10 phosphorylation at Ser50 in cultured cells, endogenous PAK4 in SGC-7901 cells was knocked down by two different small hairpin RNAs (shRNAs; #2 and #3) targeting PAK4. ShRNA #1 is a control for off target effects of the shRNA. In these experiments, SCG10 phosphorylation at Ser50 was assayed by western blotting using the phospho-Ser50-specific antibody. The efficacy of PAK4 shRNA was demonstrated by depletion of PAK4. These results clearly showed that knockdown of PAK4 inhibited SCG10 phosphorylation at Ser50 (Figure 1f ). Taken together, our findings suggest that SCG10 is a PAK4-binding protein that is phosphorylated on serine 50 by PAK4 kinase.
PAK4-mediated SCG10 phosphorylation downstream of Cdc42 and hepatocyte growth factor (HGF) Previous studies have shown that PAK4 was an effector of activated Cdc42, 3 we wanted to investigate whether PAK4-mediated SCG10 phosphorylation was downstream of activated Cdc42. Our results indicated that PAK4 further facilitated SCG10 phosphorylation on serine 50 in the presence of activated Cdc42 (Cdc42Q61L; Figure 1g , lanes 1 and 2). Depletion of the endogenous PAK4 resulted in a reduction of SCG10 phosphorylation induced by activated Cdc42 (Figure 1g , lane 3 and 4), which suggest that activated Cdc42 promotes upregulation of SCG10 phosphorylation at Ser50 via PAK4.
Given that HGF activates PAK4, 26, 27 which phosphorylates (Figures 1c and e) and binds with SCG10 (Figure 1b) , we next determined whether HGF treatment could induce SCG10 phosphorylation via PAK4 kinase. Our results showed that HGF resulted in a marked increase in phosphorylation levels of endogenous SCG10 Ser50 in SGC-7901 cells. Moreover, depletion of the endogenous PAK4 by specific shRNAs resulted in a reduction of SCG10 phosphorylation following exposure to HGF (Figure 1h ), suggesting that SCG10 phosphorylation may be induced by HGF in a PAK4-dependent manner. These results therefore, appear to establish an essential role for PAK4 in SCG10 phosphorylation in response to HGF.
Phosphorylation of SCG10 facilitates cellular MT instability
Given that SCG10 is a MT-destabilizing protein, we investigated whether Ser50-phosphoryled SCG10 participated in MT stability in gastric cancer cells. It has been shown that stable MTs can be distinguished by a variety of posttranslational modifications, such as acetylation and detyrosination. 28 Immunofluorescence and western blot analyses showed that, compared with vector control and nonphosphorylatable SCG10 (SCG10S50A), wild-type SCG10 (SCG10WT) and phospho-mimicking SCG10 (SCG10S50D) dramatically decreased the amount of cellular acetylated a-tubulin (Figures 2a and c ). There were also reductions in detyrosinated a-tubulin (Glu-Tubulin; Figure 2c ) and total a-tubulin ( Supplementary Figures 3a and 2c ). We obtained similar results with other stable BGC-823 cell clones (Supplementary Figure 4) .
We next examined whether the effect of SCG10 on MT was dependent on PAK4 kinase. When PAK4 was knocked down, SCG10WT no longer affected the MTs, whereas SCG10S50D continued to decrease the amount of cellular acetylated a-tubulin and total a-tubulin (Figure 2b , Supplementary Figures 3b and 2d) . Taken together, these findings indicate that SCG10 promotes MT instability in PAK4 kinase-dependent manner.
Phosphorylation of SCG10 promotes cellular migration and invasion MT dynamics are known to have a central role in cell motility. As Ser50-phosphorylated SCG10 was shown to promote the MT instability in gastric cancer cells, we further investigated whether phosphorylated SCG10 was able to regulate MT dynamics in a manner that promoted gastric cancer cell migration and invasion. As shown in Figures 3a and b, SCG10WT and SCG10S50D promoted BGC-823 cell migration and invasion to a greater extent than vector control and SCG10S50A. However, there was no evidence to show that SCG10WT and SCG10S50D promoted the proliferation relative to that seen with SCG10S50A (Figure 3c ), suggesting that phosphorylation of SCG10 at Ser50 was not related to cell proliferation. These findings suggest that SCG10 phosphorylation at Ser50 may facilitate the migration and invasion of gastric cancer cells.
Inhibition of PAK4 attenuates SCG10 phosphorylation-mediated cellular invasion Several studies show that the PAK4 signaling pathway is aberrantly upregulated in tumors and has a key role in cancer invasion and metastasis. 14 As it was previously shown that SCG10 Ser50 acted as a substrate of PAK4, we sought to test the role of PAK4 in SGC7901 cell migration and invasion using PAK4 inhibitor LCH-7749944 and RNA interference.
LCH-7749944 was found to inhibit SGC7901 cell migration and invasion in a dose-dependent manner (Supplementary Figures 4a and 5a), consistent with the depletion of the endogenous PAK4 by specific shRNAs (Supplementary Figures 4b and 5b) . We, therefore, explored the possible correlation between the expression level of phospho-Ser50 and its ability to promote SGC-7901 cell migration and invasion.
Incubation of SGC7901 cells with LCH-7749944 exhibited a dose-dependent inhibition of SCG10 phosphorylation as shown by western blotting analysis of phospho-Ser50 (Figure 4d) . The association between phospho-Ser50 and PAK4 was validated by experiments showing that exposure to PAK4 shRNA in which PAK4 was knocked down reduced the phospho-Ser50 levels (Figure 4e ). SCG10 knockdown markedly decreased SGC-7901 cell migration (Supplementary Figure 5d) and invasion ( Figure 4f ).
As shown in Figure 4g , knockdown of PAK4 suppressed BGC-823 cell invasion induced by SCG10WT, but not that induced by SCG10S50D. Surprisingly, PAK4 markedly enhanced the invasion of BGC-823 cells overexpressing SCG10WT, but was unable to enhance the invasion of BGC-823 cells with SCG10S50A overexpression, indicating that SCG10S50A suppressed PAK4-medicated cell invasion (Figure 4h ). Taken together, these findings suggest that SCG10 phosphorylation by PAK4 has an important role in facilitating gastric cancer cell invasion.
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Phosphorylation of SCG10 enhances gastric cancer cell metastasis in vivo To examine the effect of phospho-Ser50 on gastric cancer cell metastasis in vivo, BGC-823 cells stably expressing GFP, GFP-SCG10S50A (S50A), GFP-SCG10 (WT) or GFP-SCG10S50D (S50D) were injected into nude mice via the tail vein. Seven weeks after injection, the lung and liver tissues were obtained for microscopic histological analysis. (Figures 5b and c) . Three of ten mice in the SCG10WT group and four of ten in the SCG10S50D group showed liver tumorigenicity compared with zero of ten mice in the vector control group and one of ten in the SCG10S50A group (Figures 5d-f) .
Expression of SCG10WT and SCG10S50D was both associated with reduced body weight (Figure 5g ), indicating that SCG10 phosphorylation at Ser50 might be associated with malignant tumor progression. We, therefore, concluded that SCG10 phosphorylation on Serine 50 may promote gastric cancer cell metastasis in vivo.
PAK4 expression and phosphorylation of SCG10 positively correlate with gastric cancer clinical outcome To further investigate the role of Ser50-phosphorylated SCG10 in gastric cancer, we analyzed levels of SCG10 phospho-Ser50, by western blotting, in 99 pairs of gastric cancers and matched adjacent normal gastric tissue samples. The results (Table 1) showed that high expression of SCG10 phospho-Ser50 was significantly associated with poor pT stage (Po0.05), distant metastasis (Po0.01) and poor pTNM stage (Po0.05). Consistent with our previous findings (Figure 3c) , expression of SCG10 phospho-Ser50 was not associated with tumor size (P ¼ 0.643).
To confirm this observation, we compared primary gastric tumors, metastatic gastric tumors and their adjacent normal tissues and found that metastatic gastric tumors exhibited higher phosphor-Ser50 SCG10 expression than primary gastric tumors (Figure 6a) .
We also analyzed levels of SCG10 phospho-Ser50 by immunohistochemistry in 40 gastric cancers specimen (7 metastatic tumors and 33 primary tumors). The results also showed that high expression of SCG10 phospho-Ser50 was associated with distant metastasis (P ¼ 0.013; Table 2), which indicated that the expression level of SCG10 phospho-Ser50 by immunohistochemistry are correlated with that by western blotting. Representative samples were shown in Figure 6b .
Phosphor-Ser50 SCG10 levels in gastric cancer samples were analyzed and were plotted against the levels of PAK4. As shown in Figure 6c there was a significant positive correlation between SCG10 involved gastric cancer cell metastasis Q Guo et al these two variables (r ¼ 0.585; Po0.0001 Spearman's rank correlation test). Thus, high levels of PAK4 and phosphor-Ser50 SCG10 appear to be associated with the progression and metastasis of human gastric cancer.
DISCUSSION
Recent evidence indicates that PAK4 overexpression has a critical role in the gastric cancer tumorigenesis. 29 In order to further study the potential molecular mechanisms involved in this process, we performed yeast two-hybrid screening and found that PAK4 interacts with and phosphorylates SCG10 on serine 50. We also demonstrated that phosphorylation on Ser50 by PAK4 promotes gastric cancer cell migration and invasion in vitro and promotes metastasis in vivo.
Importantly, we found that high expression of SCG10 phosphoSer50 was associated with poor pT stage, poor pM stage and poor pTNM stage in clinical gastric cancer. These findings suggest, what we believe to be, a novel function of SCG10 in which it associates with an invasive phenotype of clinical gastric cancer though phosphorylation at Ser50.
Increasing evidence suggests that PAK4 signaling pathways have a central role in cancer cell migration and invasion. It has been shown that PAK4 has the potential to enhance cell migration and invasion through HGF/LIMK1/cofilin pathways in prostrate cancer cells 27 and by MEK-1/ERK1/2/MMP2 pathways in ovarian cancer cells.
14 The Rho-dependent activity of GEF-H1 phosphorylated on Ser810 by PAK4 has been shown to result in the formation of lamellipodia in NIH3T3 cells. 30 Other researchers have proposed that CDK5RAP3 may promote hepatocellular carcinoma-cell invasiveness by activation of PAK4 kinase activity. 31 Here, we demonstrate that SCG10 phosphorylation is involved in PAK4-mediated gastric cancer metastasis by regulating MT dynamic instability. This is the first time that the association between PAK4 and SCG10 has been demonstrated. These findings also identify a new way that PAK4-mediated SCG10 phosphorylation promotes cancer cell invasion and metastasis.
Previous studies have shown that PAK4 was an effector of activated Cdc42. 3 In this study, we found that PAK4 collaborates with activated Cdc42 for the phosphorylation of SCG10 at Ser50, and that Ser50-phosphorylated SCG10 promotes the MT instability of gastric cancer cells. These findings suggest that activated Cdc42 in cooperation with PAK4 might be involved in the regulation of MT stability.
The interaction between activated Cdc42 and PAK4 has been reported to be essential for reorganization of the actin cytoskeleton and for filopodia formation. 3 Taken together, these results suggest that PAK4 might act as a key intermediate regulatory factor involved in Rho GTPase-mediated MT and actin cytoskeleton crosstalk.
It has been proposed that PAK4 activity can be induced in Rho GTPase-dependent and -independent manners. Independent of Rho GTPase, PAK4 has been shown to be activated by HGF via phosphoinositide 3 kinase (PI3K) in prostate-derived cancer cell 27 PAK4 mRNA expression has been shown to be induced by human chorionic gonadotropin (hCG) in choriocarcinoma cell lines JEG3 and JAR. 32 The upregulation of PAK4 by follicle stimulating hormone (FSH) in ovarian cancer cells suggests that FSH is a putative upstream mediator accounting for PAK4 overexpression in ovarian cancer cells.
14 In this study, we demonstrate that SCG10 phosphorylation on serine 50 was activated not only by activated Cdc42 collaborating with PAK4, but also by a HGF-PAK4 signaling pathway, suggesting that SCG10 stimulation by PAK4 also occurs in both Rho GTPase-dependent and -independent manners.
We also established, for the first time, that there was a relationship between PAK4 and SCG10 in gastric cancer cells. SCG10 is thought to have a critical role in maintaining MT homeostasis, which can be reversed by phosphorylation modifications of SCG10. 17, 19 Phosphorylation of SCG10 both on serine 62 and 73 by C-Jun NH 2 -terminal kinase 1 (JNK1) has been shown to limit the rate of multipolar transition and neuronal migration during cortical development. 21 Our results show that the phosphorylation of SCG10 on serine 50 by PAK4 regulates MT dynamics to promote gastric cancer cell migration and invasion in vitro. It also appears to promote metastasis in a xenograft mouse model. These findings are consistent with SCG10 phosphorylation on serine 50 retaining the ability to depolymerize MTs. 23 However, it is possible that phosphorylation of SCG10 by PAK4 also affects other cellular processes that influence gastric cancer cell migration and invasion. For example, crosstalk between MT and the actin cytoskeleton and Rho GTPase may also be involved in these processes. 33, 34 Regardless of the contribution from other mechanisms, our results provide strong evidence that SCG10 is a key downstream effector of PAK4 that is involved in regulating cell migration and invasion in gastric cancer.
Stathmin 1 has been correlated with more invasive phenotypes of some human cancer types including sarcomas, gastric cancer, prostate cancer, Wilms tumors, non-small-cell lung cancers and breast cancers. 28, [35] [36] [37] [38] [39] SCG10 is generally considered to be a neuron-specific protein. 24, 25 In this study, we detected SCG10 expression in a variety of gastric cancer cell lines and also in primary tumor. Although the expression of SCG10 was not upregulated in tumor tissues compared with adjacent normal tissue, the degree of phosphorylation of SCG10 at Ser50 dramatically increased. Our results, therefore, indicate that phosphoSer50 is a novel regulatory mechanism by which SCG10 promotes gastric cancer cell invasiveness. The fact that inhibition of Ser50 phosphorylation suppressed gastric cancer cells invasion in vitro and metastasis in mouse xenografts raises the possibility of inhibiting Ser50 phosphorylation in prevention of gastric caner metastasis.
In summary, we report that the potential function of the PAK4-SCG10 axis in gastric cancer metastasis is mediated by facilitating phosphorylation-dependent MT dynamic instability. Notably, we showed that there is a strong positive correlation between PAK4 and phospho-Ser50 SCG10 expression, and that expression of SCG10 phospho-Ser50 is positively correlated with an aggressive phenotype of clinical gastric cancer. We demonstrated a novel function of SCG10 in promoting invasive potential of gastric cancer cells, suggesting that inhibiting Ser50 phosphorylation of SCG10 might be a potential therapeutic strategy for metastasis of gastric cancer. SGC-7901, MGC-803, BGC-823, GES-1 and HEK-293 cells were maintained in Dulbecco's modified Eagle's medium (Gibco, Los Angeles, CA, USA). MKN1 and MKN45 were propagated in RPMI 1640 medium (Gibco) and AGS cell line was propagated in F-12 medium (Gibco). All media were supplemented with 10% fetal bovine serum, and all cell lines were cultured at 37 1C in a humidified incubator at 5% CO 2 .
MATERIALS AND METHODS
PAK4-lentivirus and PAK4-RNAi-lentivirus were purchased from Shanghai GeneChem Company (Shanghai, China). The shRNA PAK4 #1 sequence was 5 0 -CTAAGAGGTGAACATGTAT-3 0 ; the PAK4 #2 sequence was 5 0 -GGATGAAC GAGGAGCAGAT-3 0 ; the PAK4 #3 sequence was 5 0 -CTTCATCAAGATTGGCG AG-3 0 and the shRNA control sequence was 5 0 -UUCUCCGAACGUGUCACGU tt-3 0 . Commercial lentivirus was used to infect BGC-823 cells in a 12-well plate with 3 mg/ml polybrene. Infected BGC-823 cells were identified by western blotting.
Cells were transfected with plasmids using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. BGC823 cells were stably transfected with the recombinant vector pEGFP-C1/SCG10WT, pEGFP-C1/SCG10S50A or the empty vector pEGFP-C1. Geneticin (800 mg/ml; Invitrogen) was used to select stable clones.
Immunoprecipitation, western blot analysis and GST pull-down assays Total protein was extracted from SGC-7901 cells and gastric cancer tissues using a Tissue Protein Extraction Kit (KeyGen, Nanjing, China) according to the manufacturer's instructions. Measurement of protein concentration was done using a BCA Protein Assay Kit (KeyGen). Total protein lysate (2 mg) was used for each immunoprecipitation using specific antibody or SCG10 involved gastric cancer cell metastasis Q Guo et al the corresponding IgG control. Protein A agarose beads (GE Healthcare, Uppsala, Sweden) were added to the cells and incubated overnight at 4 1C. Washed precipitated proteins were analyzed by western blot. The immunoprecipitation (IP), western blot and GST pull-down assays used in this study have been described previously in detail. 8 Plasmid construction, reagents and antibodies SCG10 was isolated by PCR from a human brain complementary DNA library and inserted into pEGFP-C1 (CLONTECH laboratories, Mountain View, CA, USA), pERFP-C1 (CLONTECH laboratories), pGEX-5x-1 (GE Healthcare) and pEBG vectors (a eukaryotic GST fusion vector, a gift from Dr Bruce Mayer, Raymond and Beverly Sackler Laboratory). Constitutively activated PAK4 (PAK4 NE), wild-type PAK4 (PAK4 WT) and kinase-dead PAK4 (PAK4 KM) were provided by Dr Audrey Minden (Susan Lehman Cullman Laboratory). ERFP-tagged or GST-tagged SCG10 phosphorylation site mutants S50A, S62A, S73A, S97A and S50D were prepared using a previously described single-tube 'megaprimer' PCR method. 8 His-PAK4 and Flag-PAK4 have previously been used in our laboratory. 8 His-Cdc42Q61L was a gift from Dr Bokoch GM (The Scripps Research Institute). LCH-7749944 and N2-(3-methoxyphenyl)-N4-((tetrahydrofuran-2-yl)methyl) quinazoline-2,4-diamine were prepared as described previously. 40 The following antibodies were used in the experiments: GFP, His, Flag, glyceraldehyde 3-phosphate dehydrogenase (GenScript Corporation, Nanjing, China), vinculin (Santa Cruz, Santa Cruz, CA, USA), GST (Cell Signaling, Beverly, MA, USA), PAK4 (Cell Signaling), phosphor-PAK4 Ser474/ PAK5 Ser602/PAK6 Ser560 (Cell Signaling), SCG10 (Santa Cruz), phosphor-SCG10 Ser50 (Bioss Inc., Woburn, MA, USA), acetylated tubulin (Sigma, St Louis, MO, USA), detyrosinated tubulin (Millipore, Billerica, MA, USA).
Cell migration and invasion assays
Transwell cell migration and Matrigel invasion assays were performed using boyden chambers with a polycarbonate Nucleopore membrane. Precoated filters (6.5 mm in diameter, 8-mm pore size, Matrigel 100 mg/cm 2 ) were rehydrated with 100 ml medium. 1 Â 10 5 cells in 100 ml serum-free Dulbecco's modified Eagle's medium supplemented with 0.1% bovine serum albumin were placed in the upper part of each chamber and the lower compartments were filled with 600 ml Dulbecco's modified Eagle's medium containing 10% serum as described previously. 40 Immunofluorescence SGC-7901 cells grown on glass coverslips were transiently transfected with red fluorescent protein (RFP) vector, RFP SCG10S50A, RFP SCG10WT or RFP SCG10S50D. Immunofluorescence assays were undertaken using a previously described method. 8, 41 The glass slides were analyzed using immunofluorescence microscopy (Olympus, Tokyo, Japan).
Immunohistochemistry
Paraffin-embedded gastric tumor tissues were obtained from the First Hospital of China Medical University. Five-micrometer-thick consecutive sections were cut and mounted on glass slides. The slides were deparaffinized, and rehydrated, before antigen retrieval, and blocking endogenous peroxidases. The sections were then washed three times in 0.01 mol/l PBS for 5 min each and blocked for 1 h in 5% normal goat serum. The sections were exposed to anti-phosphor-SCG10 Ser50 (1:100) and anti-PAK4 (1:200) 4 1C overnight. After brief washes in 0.01 mol/l PBS, sections SCG10 involved gastric cancer cell metastasis Q Guo et al were exposed for 2 h to 0.01 mol/l PBS-containing horseradish peroxidaseconjugated goat anti-rabbit immunoglobulin G (1:200), followed by development with 0.003% H 2 O 2 and 0.03% 3,3 0 -diaminobenzidine in 0.05 mol/l Tris-HCl.
All of the immunostained sections were reviewed by two authors who had no knowledge of the patients' clinical status. Five areas selected at random were scored. All sections were scored in a semiquantitative manner according to a previously described method, which reflects both the intensity and percentage of cells staining at each intensity. 42 Intensity was classified as 0 (no staining), þ 1 (weak staining), þ 2 (distinct staining) or þ 3 (very strong staining). A value designated as the 'HSCORE' was obtained for each slide by using the following algorithm: HSCORE ¼ P (I Â PC), where I and PC represent the staining intensity and the percentage of cells that stain at each intensity, respectively. And the corresponding HSCOREs were calculated separately.
To test for the specificity of the phospho-SCG10 Ser50 antibody, the antibody was preincubated for 1 h at room temperature with the peptide used for immunization at a mass ratio of 1:5, before application to the tissue slides.
Tumor metastasis formation assay in vivo BGC-823 cells with stable expression of control GFP, GFPSCG10S50A, GFPSCG10WT and GFPSCG10S50D were trypsinized, washed once with PBS and resuspended in PBS (1 Â 10 7 cells/ml). Two hundred microliters of cell solution were injected into the tail vein of 5-to 6-week-old female BALB/c mice (Vital River Laboratory Animal Technology Co. Ltd., Beijing, China). Seven weeks after injection, the mice were killed with anesthesia. The lungs and livers were extracted and fixed in 4% paraformaldehyde in phosphate-buffered saline. Lungs and liver tissues were embedded in paraffin, sectioned and stained with hematoxylin and eosin. Visible lung and liver metastases were measured and counted using a microscope.
All experimental procedures involving animals were conducted in accordance with the Guide for the Care and Use of Laboratory Animals (NIH publication no. 80-23, revised 1996) and were performed according to the institutional ethical guidelines for animal experiments.
Tissue samples
Samples of human gastric cancer tissues and paired-adjacent non-tumor gastric tissues further than 5 cm from the tumors were obtained from 99 patients undergoing radical gastric resection at the First Hospital of China Medical University. Fresh samples were snap frozen in the liquid nitrogen immediately after resection and stored at À 80 1C. All samples were obtained with patients' informed consent.
The samples were histologically confirmed by staining with hematoxylin and eosin. The histological grade of cancers was assessed according to criteria set by the World Health Organization. The tumor-node-metastasis stage was performed using the standard criteria of the seventh tumornode-metastasis staging system.
Statistical analysis
Statistical analyses were performed using SPSS version 16.0 software. Continuous data were presented as means and standard deviation ( ± s.d.). Kruskal-Wallis and Mann-Whitney tests were used to analyze associations between SCG10 phosphorylation at Ser50 expression and clinical features. Associations between variables were analyzed using Spearman's rank correlation test. Assays for cell experiments were analyzed using Student's test. Values of Po0.05 were considered statistically significant.
